Back to Journals » Risk Management and Healthcare Policy » Volume 3

Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?

Authors Clem JR, Strain JD, Farver D

Published 22 December 2009 Volume 2010:3 Pages 1—11


Review by Single-blind

Peer reviewer comments 2

James R Clem1, Joe D Strain2, Debra K Farver3

1South Dakota State University College of Pharmacy Sioux Falls, South Dakota, USA; 2South Dakota State University College of Pharmacy, Rapid City Regional Hospital, Rapid City, South Dakota, USA; 3South Dakota State University College of Pharmacy, Yankton, South Dakota, USA

Abstract: Cardiovascular disease remains the leading cause of death in the world. A significant amount of clinical data are available to demonstrate the positive influence that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has on slowing the progression of cardiovascular disease and improving clinical outcomes. Achieving the treatment goals for cholesterol in cardiovascular disease continues to present challenges. Recent clinical trial information is available assessing the use of more aggressive initial doses of statin therapy based on initial low-density lipoprotein cholesterol (LDL-C) measurements in an attempt to reach treatment goals sooner. Six clinical trials assessed low-, moderate- and high-risk individuals as well as those with type 2 diabetes mellitus to determine if this treatment approach is both safe and effective. The studies concluded that initial dosing of statin therapy determined by a baseline LDL-C measurement demonstrates good achievement in reaching treatment goals and does not result in a higher rate of adverse effects.

Keywords: LDL-C, statin therapy, treatment goals

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other article by this author:

New advances in the treatment of Clostridium difficile infection (CDI)

Dennis D Hedge, Joe D Strain, Jodi R Heins, Debra K Farver

Therapeutics and Clinical Risk Management 2008, 4:949-964

Published Date: 10 October 2008

Readers of this article also read:

Monitoring cancer stem cells: insights into clinical oncology

Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL

OncoTargets and Therapy 2016, 9:731-740

Published Date: 11 February 2016

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Applications of coxsackievirus A21 in oncology

Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F

Oncolytic Virotherapy 2014, 3:47-55

Published Date: 10 April 2014

Cancer patient-centered home care: a new model for health care in oncology

Tralongo P, Ferraù F, Borsellino N, Verderame F, Caruso M, Giuffrida D, Butera A, Gebbia V

Therapeutics and Clinical Risk Management 2011, 7:387-392

Published Date: 9 September 2011

Multidisciplinary care in pediatric oncology

Cantrell MA, Ruble K

Journal of Multidisciplinary Healthcare 2011, 4:171-181

Published Date: 30 May 2011

Use of electronic medical records in oncology outcomes research

Gena Kanas, Libby Morimoto, Fionna Mowat, et al

ClinicoEconomics and Outcomes Research 2010, 2:1-14

Published Date: 24 February 2010